ReviewDrugs2019
Contemporary Options for the Management of Motor Complications in Parkinson's Disease: Updated Clinical Review.
Review in Drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Comparative efficacy and safety of six non-ergot dopamine-receptor agonists in early Parkinson's disease: a systematic review and network meta-analysis.Frontiers in neurology · 2023Pooled it
- The Comparative Efficacy of Non-ergot Dopamine Agonist and Potential Risk Factors for Motor Complications and Side Effects From NEDA Use in Early Parkinson's Disease: Evidence From Clinical Trials.Frontiers in aging neuroscience · 2022Pooled it
- Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson's Disease: A Systematic Review.Movement disorders : official journal of the Movement Disorder Society · 2021Pooled it
- Improvements in clinical signs of Parkinson's disease using photobiomodulation: a prospective proof-of-concept study.BMC neurology · 2021Trial
- Effect of COMT and UGT1A Variants on Clinical Response to Opicapone in Parkinson's Disease.Movement disorders clinical practice · 2026Article
- AI-Driven Analysis of Wrist-Worn Sensor Data for Monitoring Individual Treatment Response and Optimizing Levodopa Dosing in Parkinson's Disease.Sensors (Basel, Switzerland) · 2025Article
- Mitigation of Neuroinflammation and Oxidative Stress in Rotenone-Induced Parkinson Mouse Model through Liposomal Coenzyme-Q10 Intervention: A Comprehensive In-vivo Study.Inflammation · 2025Article
- The role of L-DOPA in neurological and neurodegenerative complications: a review.Molecular and cellular biochemistry · 2025Review
- Molecular pathways: the quest for effective MAO-B inhibitors in neurodegenerative therapy.Molecular biology reports · 2025Review
- Levodopa/carbidopa/entacapone versus levodopa/benserazide plus pramipexole in Chinese patients with Parkinson's disease experiencing wearing off.Frontiers in neurology · 2025Article
- Exceeding the Limits with Nutraceuticals: Looking Towards Parkinson's Disease and Frailty.International journal of molecular sciences · 2024Review
- Efficacy and safety of non-ergot dopamine-receptor agonists as an adjunct to levodopa in advanced Parkinson's disease: A network meta-analysis.European journal of neurology · 2023Review
- Absorption, metabolism and excretion of opicapone in human healthy volunteers.British journal of clinical pharmacology · 2022Article
- Guidelines for Parkinson's disease treatment: consensus from the Movement Disorders Scientific Department of the Brazilian Academy of Neurology - motor symptoms.Arquivos de neuro-psiquiatria · 2022Article
- Metabolism and disposition of opicapone in the rat and metabolic enzymes phenotyping.Pharmacology research & perspectives · 2022Article
- Difference in rural and urban Medicare prescription pattern for Parkinson's disease in Hawai'i.Clinical parkinsonism & related disorders · 2022Article
- CASTELO: clustered atom subtypes aided lead optimization-a combined machine learning and molecular modeling method.BMC bioinformatics · 2021Article
- Opicapone: A Review in Parkinson's Disease.CNS drugs · 2021Review
- Istradefylline to Treat Patients with Parkinson's Disease Experiencing "Off" Episodes: A Comprehensive Review.Neurology international · 2020Review
- Intrastriatal administration of coenzyme Q10 enhances neuroprotection in a Parkinson's disease rat model.Scientific reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a chronic, progressive condition affecting around 1% of the population older than 60 years. Upon long-term treatment with levodopa, the mainstay of treatment in PD, most patients, especially younger ones exposed to higher doses, will experience symptoms related to end-of-dose deterioration, peak-dose dyskinesias, and other motor fluctuations. Therapeutic strategies are grounded on modification of oral levodopa pharmacokinetics to extend levodopa benefit and development of new routes of drug delivery (e.g., levodopa/carbidopa intestinal gel infusion) or long-acting formulations of existing dopaminergic drugs to prolong the duration of striatal dopamine receptors stimulation. As our understanding of the pathophysiology of motor complications evolves, our therapeutic armamentarium is actively expanding and the focus of research is now actively pointing to the new non-dopaminergic agents acting both within the basal ganglia and in other brain regions (e.g., drugs acting on glutamate, GABA, serotonin, and calcium channels). Despite the fact that trials comparing the different therapeutic strategies are lacking, we aimed at devising practical evidence- and experience-guided suggestions for the clinical management of motor complications, emphasizing that this should always be an individualized endeavor. This review summarizes the pharmacological management of motor complications in PD, including new formulations and routes of delivery, and the newer released drugs such as istradefylline, opicapone, safinamide, and zonisamide. Advanced therapeutic strategies for selected cases such as treatment with apomorphine and surgical techniques (deep brain stimulation) are also discussed. A comprehensive knowledge of the available options and evidence is fundamental for the successful management of these challenging complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.